Broadly neutralizing antibodies (bnAbs) elicited in HIV-1+ elite neutralizers typically are unable to reduce viremia in the same individuals from whom they are isolated. A recent study reports the development of bnAbs in an elite controller that, along with the help of T cells, were associated with restricting HIV-1 progression.
© 2001-2025 Fundación Dialnet · Todos los derechos reservados